Lung Cancer Study
NSLI 0817: A Phase 2 Study of Cisplatin + Pemetrexed + Avastin (bevacizumab) as First Line Therapy in patients with Advanced Non-Squamous Nonsmall Cell Lung Carcinoma
Protocol ID
Protocol Description
The primary goal of this study is to determine whether a combination of certain chemotherapy drugs - cisplatin, pemetrexed, and Avastin, when given to recently diagnosed patients with non-small cell lung cancer (NSCLC), can lengthen the time it takes their tumor to grow and therefore make them live longer.
This study is being conducted in order to determine 1) whether this drug combination is safe, 2) what possible sideeffects there might be and, 3) whether or not the combination of these 3 drugs is at least as effective as Avastin in combination with carboplatin and paclitaxel for the treatment of NSCLC.
Eligibility Criteria
Patients with non-small cell lung cancer
Primary Investigator(s)
- Haralambos Raftopoulos, MD